A single low-cost assay replaces what currently requires several different tests.
Among the most common and consequential diagnoses a child can receive, pediatric leukemia has long demanded both speed and precision that existing tools struggled to deliver together. Researchers at the University of North Carolina have now introduced FUSILLI, a diagnostic algorithm built on long-read nanopore sequencing, designed to detect the gene fusions that drive B-cell acute lymphoblastic leukemia with greater sensitivity, lower cost, and faster turnaround than conventional methods. The work reflects a broader convergence in modern medicine — the maturation of sequencing technology meeting the urgent human need to match each child's cancer to the treatment most likely to spare them harm while offering the best chance of survival.
- Children with B-ALL face treatment decisions that hinge entirely on identifying the correct genetic subtype — a misread can mean too little therapy, allowing cancer to advance, or too much, inflicting lasting toxic harm.
- Current diagnostic approaches require multiple specialized assays, expensive equipment, and weeks of waiting — barriers that are especially acute in rural hospitals and under-resourced settings worldwide.
- FUSILLI uses Oxford Nanopore long-read sequencing to examine larger stretches of genetic material at once, catching more genuine fusions while filtering out the artificial chimeras that confound other tools.
- At roughly 10 million reads per sample, the tool replaces a multi-test diagnostic workflow with a single, faster, lower-cost run — compressing weeks into days.
- The research also surfaced secondary genetic alterations, including the understudied PAX5::ZCCHC7 fusion, hinting that deeper genomic visibility could further sharpen risk stratification and personalized treatment.
- The findings, published in The Journal of Molecular Diagnostics, now face the critical transition from research validation to clinical deployment — the step that will determine whether FUSILLI's promise reaches the children who need it.
Pediatric leukemia is the most common childhood cancer, and its most prevalent form — B-cell acute lymphoblastic leukemia — is driven by specific gene fusions that determine how the disease should be treated. For years, identifying those fusions has required expensive equipment, multiple specialized tests, and waiting periods measured in weeks. A research team at the University of North Carolina, led by geneticist Jeremy R. Wang, set out to change that with a tool called FUSILLI.
FUSILLI stands for FUSions In Leukemia for Long-read sequencing Investigator. It is built on Oxford Nanopore sequencing technology, which reads longer stretches of DNA and RNA in a single pass rather than breaking genetic material into tiny fragments. That approach makes the process faster and cheaper — and after roughly a decade of development, the technology is now mature enough for clinical application. The team adapted it specifically to detect the fusion genes that drive B-ALL.
The stakes of accurate detection are high. A child's treatment protocol depends on knowing their precise genetic subtype. Errors in either direction carry real consequences: under-treatment risks disease progression, while over-treatment exposes young patients to unnecessary chemotherapy toxicity. FUSILLI proved more sensitive than existing algorithms in head-to-head testing — catching more genuine fusions without generating more false positives — and the team established that approximately 10 million reads per sample provides reliable diagnostic depth.
Beyond its core performance, the tool revealed something unexpected: secondary genetic alterations, including a fusion called PAX5::ZCCHC7, appeared more frequently than conventional diagnostics typically capture. The clinical significance of these findings remains under investigation, but they suggest that broader genomic visibility could eventually support more refined, personalized treatment decisions.
Published in The Journal of Molecular Diagnostics, the research now points toward a practical next step — moving FUSILLI from the research setting into hospitals and diagnostic labs where it can directly shape how pediatric leukemia is identified and treated.
Pediatric leukemia kills children. The most common form, B-cell acute lymphoblastic leukemia, or B-ALL, accounts for roughly one in four childhood cancers. For decades, doctors have known that the disease is driven by specific genetic mutations—fusion genes that cause cancer cells to multiply uncontrollably. But finding those mutations has required expensive equipment, multiple specialized tests, and weeks of waiting. A team of researchers at the University of North Carolina has now built a tool that changes that equation.
The tool is called FUSILLI, short for FUSions In Leukemia for Long-read sequencing Investigator. It uses a newer sequencing technology called nanopore sequencing, developed by Oxford Nanopore Technologies, to read longer stretches of DNA and RNA at once. Where traditional sequencing breaks genetic material into tiny fragments and reads them separately, nanopore sequencing examines larger pieces, making it faster and cheaper to run. The method has existed for about a decade but is only now mature enough for clinical use. Jeremy R. Wang, a geneticist at UNC's School of Medicine, led the research team that adapted it specifically for detecting the fusion genes that drive B-ALL.
Why does this matter? Current treatment for B-ALL depends entirely on knowing which genetic subtype a child has. Age, white blood cell count, how the cancer responds to initial therapy, whether it has spread to the nervous system, and the specific genomic mutations all factor into the risk calculation. Get the subtype wrong, and a child might receive either too little treatment, allowing the cancer to progress, or too much, exposing them to unnecessary toxicity from chemotherapy and radiation. The stakes are not abstract. Accurate diagnosis means better survival rates and fewer long-term side effects.
The researchers tested FUSILLI against existing fusion-detection algorithms and found it more sensitive—meaning it caught more real fusions—without sacrificing specificity, which is the ability to avoid false alarms. The key challenge in fusion detection is distinguishing genuine mutations from artifacts. During sequencing, DNA strands sometimes stick together artificially, creating chimeras—fake fusion sequences that look real under the microscope. With careful filtering and enough sequencing depth, FUSILLI learned to tell the difference. The team determined that approximately 10 million reads per sample are needed to reliably detect B-ALL fusions using this approach.
The practical advantages are substantial. Nanopore sequencing requires far less expensive equipment and reagents than traditional short-read methods. Turnaround time drops from weeks to days. In resource-limited settings—rural hospitals, developing countries, clinics without access to specialized genomics labs—this matters enormously. A single low-cost assay replaces what currently requires several different expertise-intensive tests. One machine, one run, one answer.
But the research also uncovered something unexpected. While analyzing the data, the team noticed secondary genetic alterations appearing more frequently than existing diagnostic tools typically capture. One example is a fusion called PAX5::ZCCHC7, which appears in several cases and is known to be a secondary alteration but whose clinical significance remains poorly understood. These lesser-known mutations might hold clues to better risk stratification and more personalized treatment decisions. Wang notes that a deeper understanding of these genomic events could further refine how doctors tailor therapy to individual children.
The work appears in The Journal of Molecular Diagnostics, published by Elsevier. It represents a convergence of two trends in modern medicine: the maturation of long-read sequencing technology and the growing recognition that genomic precision saves lives. For children diagnosed with B-ALL, FUSILLI offers the possibility of faster answers, lower costs, and ultimately, better outcomes. The next step is moving the tool from research into clinical practice—getting it into hospitals and diagnostic labs where it can actually change how pediatric leukemia is diagnosed and treated.
Citas Notables
Long-read sequencing represents a new era of sequencing compared to conventional short-read approaches and is now becoming mature enough for clinical applications.— Jeremy R. Wang, University of North Carolina
With the development of FUSILLI, we show the potential of using a single low-cost sequencing assay for diagnosing gene fusion subtypes of B-ALL, with faster turnaround time.— Jeremy R. Wang, University of North Carolina
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this tool uses long-read sequencing instead of the short-read methods hospitals already have?
Short-read sequencing breaks DNA into tiny pieces and reads them separately. It's like trying to understand a sentence by looking at individual letters scattered on a table. Long-read sequencing looks at much larger chunks at once, so you can see the actual structure of what's happening. For gene fusions, that's crucial—you need to see how two different genes have stuck together. Long reads show you that connection directly.
The paper mentions "sequencing chimeras." What are those, and why are they a problem?
During the sequencing process, DNA strands sometimes stick together by accident, creating fake fusion sequences. They look real—they have all the hallmarks of a true mutation—but they're just artifacts of the technology. If you report a chimera as a real fusion, you've just told a family their child has a genetic subtype they don't actually have. That leads to wrong treatment decisions.
How does FUSILLI solve that problem?
It uses filtering and requires a minimum threshold of evidence. A true fusion has to show up in at least two separate reads. Chimeras are rare, so they usually appear only once. By demanding multiple independent confirmations, the algorithm filters out the noise while keeping the real signal.
You mentioned the tool needs 10 million reads per sample. Is that a lot?
Not really, compared to what you'd need with short-read sequencing. And it's achievable on a single nanopore run. The real advantage is cost—nanopore machines are far cheaper to buy and operate than traditional sequencers. In a rural hospital or a clinic in a country with limited resources, that's the difference between being able to do genomic testing and not being able to do it at all.
The researchers found unexpected secondary mutations. Why is that important?
Because it suggests the tool is catching things that existing diagnostic methods miss. Those secondary mutations might not be the main driver of the cancer, but they could influence how aggressively the cancer behaves or how well it responds to treatment. If you understand those patterns, you can refine your risk assessment and personalize therapy even further.
So this isn't just about speed and cost. It's about seeing more of the genetic picture.
Exactly. It's both. You get faster, cheaper diagnosis, but you also get more information. That's rare. Usually you trade one for the other.